NCT04015076View on ClinicalTrials.gov

Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With Inzomelid

PHASE1CompletedINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

July 16, 2019

Primary Completion Date

March 23, 2020

Study Completion Date

March 23, 2020

Conditions

Healthy

Interventions

DRUG

Inzomelid

Active Drug

DRUG

Placebo

Placebo to Match

Trial Locations (1)

Unknown

Nucleus Network, Melbourne

Sponsors

Lead Sponsor

Inflazome UK Ltd

All Listed Sponsors

lead

Inflazome UK Ltd

INDUSTRY